| Literature DB >> 35632286 |
Shamim Azimi1, Aristides Docoslis1.
Abstract
The rapid increase in illicit drug use and its adverse health effects and socio-economic consequences have reached alarming proportions in recent years. Surface-enhanced Raman scattering (SERS) has emerged as a highly sensitive analytical tool for the detection of low dosages of drugs in liquid and solid samples. In the present article, we review the state-of-the-art use of SERS for chemical analysis of illicit drugs in aqueous and complex biological samples, including saliva, urine, and blood. We also include a review of the types of SERS substrates used for this purpose, pointing out recent advancements in substrate fabrication towards quantitative and qualitative detection of illicit drugs. Finally, we conclude by providing our perspective on the field of SERS-based drug detection, including presently faced challenges. Overall, our review provides evidence of the strong potential of SERS to establish itself as both a laboratory and in situ analytical method for fast and sensitive drug detection and identification.Entities:
Keywords: Raman spectroscopy; drug detection; illicit drugs; point-of-care diagnostics; surface-enhanced Raman scattering
Mesh:
Substances:
Year: 2022 PMID: 35632286 PMCID: PMC9143835 DOI: 10.3390/s22103877
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.847
Figure 1Schematic presentation of optimum hotspot formation during D-SERS, combined with the introduction of an internal standard for the detection of fentanyl. Sketches represent a drop of Au-sol, 3D hotspots, and aggregate of Au NPs, respectively [50].
Figure 2(A) (i) Schematic presentation of SERS-active substrates and detection process. (ii) Spectra obtained for illicit drugs tested and blank sample (water deposited on Ag dendrites). (iii) Plot of first three principal components used to cluster the spectra from different illicit drug analytes for identification. Each cluster consists of 20 spectra, and ellipsoids indicate a 95% confidence interval for each group [72]. (B) Illustration of a portable kit for rapid SERS detection of drugs in real human urine [74]. (C) Steps involved in the fabrication of gold nanoparticle cluster arrays using polystyrene-block-poly(2-vinylpyridine) (PSb-P2VP) templates on a silicon or glass surface [77].
Figure 3(A) SERS substrate assembly through reduction in Ag ions on the edges of interdigitated Au electrodes. (B) electrodes act as a template for the electrochemical growth of Ag nanostructures [88].
Summary of experimental factors, studied in terms of their influence on the performance of SERS substrates.
| Experimental Factor Investigated | Reference |
|---|---|
| Nanoparticle aggregation agent, aggregation time, pH | [ |
| Nanoparticle size, capping agent, excitation wavelength | [ |
| SERS substrate material | [ |
| 3D structure and surface topography of substrate | [ |
| Chemical surface functionalization of SERS substrates | [ |
Figure 4Schematic presentation of SERS substrate functionalization and drug detection process. (A) Chemically synthesized Au TNPs in acetonitrile are immobilized onto an APTES-functionalized glass substrate through incubation. (B) Au TNPs are functionalized with PEG-thiolate. (C) Adhesive tape is placed on the Au TNP-containing a glass substrate (D) Au TNPs are lift off from the glass to the tape. (E) human biofluids drop-casted directly onto the nanosensor resulting in physisorption of drugs onto TNPs. (E) SERS spectra collection. (F) Bluish gray area in the photograph is the plasmonic patch and the overall construct resembles with Band-Aid [94].
Figure 5Flow-focusing microfluidic device used for controlled Ag-NP aggregation [105]. (A) Ag-NP suspension, a saliva sample, and salt solution are loaded in the device and driven through it by a vacuum pump. (B) At the flow-focusing junction, the sample stream is enveloped by the side-streams and diffusion drives lateral mass transport between the laminar flows, here visualized with a fluorescent dye. (C) Ag NP, analyte, and salt solution are introduced to the channel from the left and flow toward the right. Analyte molecules resident in the focused stream diffuse laterally into the side flows. Salt ions also diffuse into the colloid stream inducing controlled nanoparticle aggregation, creating SERS-active clusters that convect downstream [105].
Figure 6(A) Schematic and the corresponding optical images of the self-assembly of Ag NPs into spherical Ag colloidal superstructures. (i) The addition of CYH-dispersed Ag NPs into SDS aqueous phase. (ii) An oil-in-water emulsion through vigorous stirring. (iii) The as-prepared sols of spherical superstructures after the evaporation of oil. (B) Schematic of SERS platform for sensing analytes located in the 3D geometrical gaps of colloidal superstructures. (C) TEM image of a single 3D colloidal superstructure [116].
Figure 7Baseline-corrected SERS spectra of 100 μM codeine spiked into (A) water (B) human plasma [122].
Applications of SERS analyses of illicit drug detection.
| Drug | Matrix | Analysis Type | SERS Substrate | Laser Line | Limit of Detection | Reference |
|---|---|---|---|---|---|---|
| Amphetamine | Aqueous solution | Quantitative | Ag colloidal solution | 532 | 5 µg | [ |
| Benzocaine | Aqueous solution | Quantitative | Au@Ag nanocube-based plasmene nanosheets | 514 | 0.9 × 10−6 gr·cm−2 | [ |
| Cannabinol | Aqueous solution | Quantitative | vertically aligned hexagonally close-packed AuNR arrays | 632.8 | 1 µM | [ |
| Cannabinoids | Aqueous solution | Quantitative | Colloidal AuNPs | 785 | 18–60 ng·mL−1 | [ |
| Chrysoidin | Aqueous solution | Quantitative | AuNSt-GO-AuNSt sandwich structure | 785 | 1 nm | [ |
| Cocaine | Saliva | Semi- | Au doped sol-gel capillary | 785 | 50 ppb | [ |
| Cocaine | Human saliva | Semi- | fused gold colloids trapped in a porous glass | 785 | 50 ng·mL−1 | [ |
| Cocaine | Saliva | Quantitative | gold nanorods colloidal solution | 780 | 10 ng·mL−1 | [ |
| Cocaine | Aqueous solution | Quantitative | (AuNP)-embedded paper swab | 785 | 0.6 ng | [ |
| Cocaine | Saliva | Quantitative | Dendritic silver nanostructures | 632.8 | 100 ppb | [ |
| Cocaine | Human Urine | Semi- | Self-assembly of 2D AuNPs film | 633 nm | 500 ppb | [ |
| Cocaine | Aqueous solution | Semi | Colloidal AuNPs integrated with microfluidic | 633 | 4.6 ng·mL−1 | [ |
| Cocaine | Aqueous solution | Quantitative | Ag colloidal | 532 | 5.0 µg | [ |
| Codeine | Human Saliva | Quantitative | Au doped sol-gel capillary | 785 | 25 ng·mL−1 | [ |
| Codeine | Human Plasma | Quantitative | Colloidal AgNPs | 633 | 1.39 µM | [ |
| Dopamine | Aqueous solution | Quantitative | Colloidal ANPs | 532 | 20 pM | [ |
| Erythrosine B | Aqueous solution | Quantitative | AuNSt-GO-AuNSt sandwich structure | 785 | 1 nm | [ |
| Fentanyl | Aqueous solution | Quantitative | (AuNP)- | 785 | 1.0 ng | [ |
| Fentanyl | Aqueous solution | Quantitative | Dendritic silver nanostructures | 632.8 | 0.078 ppm | [ |
| Fentanyl | Urine | Quantitative | AuNPs assembled on filter | 785 | 10 ppb | [ |
| MDMA | Aqueous solution | Quantitative | D-SERS | 10 µM | [ | |
| MDMA | Human Urine | Quantitative | 2D-GNR assembled by (mPEG-SH) capping | 785 | 0.1 ppm | [ |
| MDMA | Aqueous solution | Quantitative | Colloidal AgNPs modified by | 785 | 1.5 × 10−5 M | [ |
| MDMA | Human Urine | Semi-quantitative | Au nanorods stabilized with SH-PEG | 785 | 0.1 ppm | [ |
| Meperidine | Aqueous solution | Quantitative | Ag colloidal | 532 | 3 µM | [ |
| Methadone | Human plasma | Semi-quantitative | Silver halide dispersed into the wells of | - | 1 µg/sample | [ |
| Methamphetamine/2-MNA | Aqueous solution | Quantitative | Etched Ag foil | 633 nm | 17 ppm | [ |
| Methamphetamine | Human Urine | Semi-quantitative | Au nanorods | 785 | 0.1 ppm | [ |
| Methamphetamine | Human saliva | Semi-quantitative | Colloidal AgNPs integrated with microfluidics | 633 | 10 nm | [ |
| Morphine | Aqueous solution | Semi-quantitative | Colloidal AuNPs integrated with microfluidic | 633 | 13 ng·mL−1 | [ |
| Tramadol | Artificial Urine | Quantitative | Hydroxylamine AgNPs | 633 nm | 2.5 × 10−6 M | [ |
| Tramadol | Aqueous solution | Quantitative | Hydroxylamine AgNPs | 633 nm | 5 × 10−4 M | [ |
| Phencyclidine | Human saliva | Sem-quantitative | fused gold | 785 | 1 µg·mL−1 | [ |